ALTO
ALTO-207-201 is a phase 2b clinical research trial. Participants must have been previously diagnosed with Major Depressive Disorder (MDD), and need to have tried two to five antidepressant treatments with minimal improvement in their depression symptoms.
The purpose of this research study is to compare the effectiveness of the study drug in treating symptoms of depression when combined with a traditional anti-depressant medication. In addition, this trial aims to evaluate study drug safety, measure how the study drug moves through the body over time and understand the brain activity patterns, thinking and behavior that can be seen in participants with treatment resistant depression prior to and while taking the study drug. The research study will take up to 17 weeks and require onsite visits in Worcester, MA.
More information regarding the trial can be found here: https://clinicaltrials.gov/study/NCT07553637 If you are interested in pursuing this trial please contact Patricia Arruda, RN Clinical Trial Manager at 508-425-6189 or patricia.arruda@reliantmedicalgroup.org
Individualizing Treatment for Asthma in Primary Care (iTREAT)
While asthma therapy is becoming more individualized based on asthma phenotypes, more research is needed to tailor newer therapies to individuals. The iTREAT study will compare two currently available approaches to reduce asthma exacerbations in primary care patients. These treatments will be studied both individually and in combination. More information can be found here: https://clinicaltrials.gov/study/NCT07052942
If you are interested in pursuing this trail please contact Theodore Girard, RN Clinical Trail Manager at 508-595-2105 or theodore.girard@reliantmedicalgroup.org and Lucia Sears at 508-425-6132 or lucia.sears@reliantmedicalgroup.org
CodeBreaK
CodeBreaK 202 is a interventional study for patients with non-small cell lung cancers with Stage IV or Advanced Stage IIIB/C disease. The primary goal is to compare the survival rate after treatment with either Sotorasib Platinum Doublet Combination or Pembrolizumab Platinum Doublet Therapy. More information can be found here: https://clinicaltrials.gov/study/NCT05920356?term=NCT05920356&rank=1
If you are interested in pursuing this trial please contact Patricia Arruda, RN Clinical Trial Manager at 508-425-6189 or patricia.arruda@reliantmedicalgroup.org and Jennifer Duffy, RN Clinical Trial Manager at 508-595-2219 or jennifer.duffy@reliantmedicalgroup.org
SUNRAY
SUNRY-02 is a phase 3 clinical drug trial. The purpose of this study is to learn more about olomorasib, a possible new treatment for lung cancer. The study aims to learn whether it can prevent cancer from returning for a longer period of time, whether it works better than a placebo (a pretend drug) and what are the possible side effects. Patients enrolled in this study will be randomized to take either olomorasib or a placebo drug in addition to standard treatments. More information can be found here: https://clinicaltrials.gov/study/NCT06890598.
If you are interested in pursuing this trial please contact Patricia Arruda, RN Clinical Trial Manager at 508-425-6189 or patricia.arruda@reliantmedicalgroup.org and Jennifer Duffy, RN Clinical Trial Manager at 508-595-2219 or jennifer.duffy@reliantmedicalgroup.org
